Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT05359653 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT05359653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05359653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Lead sponsor
University of California, San Francisco
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 1, 2023
Completion date
June 1, 2027
Enrollment
74 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis (ms), multiple sclerosis benign, multiple sclerosis brain lesion, multiple sclerosis relapse, multiple sclerosis, chronic progressive, multiple sclerosis, primary progressive, multiple sclerosis, relapsing-remitting